Puissance Life Science Opportunities Fund VI 13D and 13G filings for Bellerophon Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-10-17 9:05 pm Unchanged | 2023-10-17 | 13D | BELLEROPHON THERAPEUTICS INC C BLPH | Puissance Life Science Opportunities Fund VI | 1,211,262 0.500% | 0 (Unchanged) | Filing |
| 2023-10-16 8:56 pm Unchanged | 2023-10-07 | 13D | BELLEROPHON THERAPEUTICS INC C BLPH | Puissance Life Science Opportunities Fund VI | 1,211,262 0.500% | 0 (Unchanged) | Filing |
| 2023-06-07 9:44 pm Sale | 2023-06-07 | 13D | BELLEROPHON THERAPEUTICS INC C BLPH | Puissance Life Science Opportunities Fund VI | 1,211,262 10.900% | -60,913 (-4.79%) | Filing |
| 2023-05-22 07:04 am Sale | 2023-05-18 | 13D | BELLEROPHON THERAPEUTICS INC C BLPH | Puissance Life Science Opportunities Fund VI | 1,272,175 12.200% | -551,815 (-30.25%) | Filing |